| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H21FN4O |
| Molecular Weight | 376.4267 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(CCN2CCN(CC2)C(=O)C3=CC=CC4=C3NC=C4C#N)C=C1
InChI
InChIKey=AQRLDDAFYYAIJP-UHFFFAOYSA-N
InChI=1S/C22H21FN4O/c23-18-6-4-16(5-7-18)8-9-26-10-12-27(13-11-26)22(28)20-3-1-2-19-17(14-24)15-25-21(19)20/h1-7,15,25H,8-13H2
| Molecular Formula | C22H21FN4O |
| Molecular Weight | 376.4267 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pruvanserin (EMD 281014, LY-2422347) is a selective serotonin 5-HT2A receptor antagonist. Pruvanserin was originated by Merck KGaA. Eli Lilly had been developing pruvanserin, under a global licence from Merck KGaA, for the treatment of primary insomnia and major depressive disorder. Phase II trials were completed in the US, Hungary and Spain. However, development appears to have been discontinued.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Eli Lilly had completed a multicentre phase II trial of pruvanserin in the US (9951; H9U-MC-MDBD; NCT00259311). The trial assessed the safety and efficacy of 5 and 15mg doses versus placebo in approximately 400 patients with primary insomnia.
Route of Administration:
Oral
